TOP > 外国特許検索 > NUCLEIC ACID DELIVERY CARRIER, NUCLEIC ACID DELIVERY KIT, AND NUCLEIC ACID DELIVERY METHOD

NUCLEIC ACID DELIVERY CARRIER, NUCLEIC ACID DELIVERY KIT, AND NUCLEIC ACID DELIVERY METHOD UPDATE

外国特許コード F170009132
整理番号 S2017-0179-N0
掲載日 2017年7月20日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP067382
国際公開番号 WO 2016199895
国際出願日 平成28年6月10日(2016.6.10)
国際公開日 平成28年12月15日(2016.12.15)
優先権データ
  • 特願2015-117429 (2015.6.10) JP
発明の名称 (英語) NUCLEIC ACID DELIVERY CARRIER, NUCLEIC ACID DELIVERY KIT, AND NUCLEIC ACID DELIVERY METHOD UPDATE
発明の概要(英語) The purpose of the present invention is to provide a nucleic acid delivery carrier, a nucleic acid delivery kit, and a nucleic acid delivery method which have an excellent effect of inhibiting cell death after nucleic acid delivery and have excellent efficiency of delivering nucleic acids into cells. This carrier for delivery of nucleic acids into cells comprises a ribosome having a membrane fusion capability, wherein the ribosome includes a cationic lipid as a membrane constituent, and the surface of the ribosome is modified with a temperature-responsive polymer. This nucleic acid delivery carrier is optimally used to deliver nucleic acids into cervical cancer cells. This kit for delivering nucleic acids into cells includes the aforementioned delivery carrier. The nucleic acid delivery method for delivering nucleic acids into cells involves a step for contacting isolated cells with a complex of the aforementioned nucleic acid delivery carrier and nucleic acids, or, a step for dosing a non-human animal with a complex of the aforementioned nucleic acid delivery carrier and nucleic acids.
従来技術、競合技術の概要(英語) BACKGROUND ART
In gene therapy, nucleic acid such as siRNA intravenous administration alone, and the uptake by the reticuloendothelial system (RES) such as by dissolution with a nuclease, layers and to from blood, such as siRNA into target cells is difficult to reach the nucleic acid. Therefore, more efficient nucleic acid suitable for delivering to the target cell, a drug delivery system is a carrier for (Drug Delivery System: DDS), which is conventionally required.
On the other hand, in recent years, the use of a liposome to DDS has attracted attention. Liposomes, the lipid bilayer cell membrane structure similar to that of the spherical particles, to form a complex with a nucleic acid with nucleic acid can be kept in a stable, also used DDS of the nucleic acid.
For example, lipofectamine (registered trademark) manufactured by Invitrogen (see non-patent document 1) is, and efficiently DDS siRNA into cells can be delivered as a carrier, are used in the related art.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KEIO UNIVERSITY
  • 発明者(英語)
  • KANAZAWA HIDEKO
  • WANG JIAN
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記問合せ先にご相談下さい。

PAGE TOP

close
close
close
close
close
close